

This document is made available through the declassification efforts
and research of John Greenewald, Jr., creator of:

The Black Vault



The Black Vault is the largest online Freedom of Information Act (FOIA) document clearinghouse in the world. The research efforts here are responsible for the declassification of MILLIONS of pages released by the U.S. Government & Military.

Discover the Truth at: <http://www.theblackvault.com>

114

24 March 1969

MEMORANDUM FOR THE RECORD

SUBJECT: Meeting with
of the Bureau of Narcotics and Dangerous Drugs

1. On 8 April 1968, Reorganization Plan 1 of 1968 transferred the Bureau of Narcotics from the Department of the Treasury and the Bureau of Drug Abuse Control from the Department of Health, Education, and Welfare to the Department of Justice and created the Bureau of Narcotics and Dangerous Drugs under the direction of [redacted] Within the new bureau, [redacted] is Chief of Intelligence, Dr. [redacted] is Chief of Laboratory Operations in the Office of Science and Education and [redacted] is Chief of the Organized Crime Division. [redacted] a previous Agency employee on the Staff, holds a Top Secret Agency clearance. Mr. [redacted] and Dr. [redacted] are ex-employees of the FBI and hold Secret Agency clearances.

2. In order to gain perspective on the new bureau's operations, Drs. [redacted] met with the above named individuals in Mr. [redacted] on 19 March 1969. The general discussion that followed revealed that:

a. Clandestine drug manufacturing is rather extensive with BNDD Agents having broken up 42 clandestine operations as of 1 year ago, 36 of these making hallucinogens.

b. Principal ethical sources of LSD at this time are [redacted] and [redacted] The [redacted] are sensitive to the illicite use problem [redacted]

[redacted] The [redacted] are a different problem, however.

7D

b2, b5

This is being remedied and they expect greater efficiency will result.

Page 2

d. Analytical methods for detection and identification of drugs are constantly under study and review with emphasis on techniques.
Also, current funding may include research at

3. At this point, Drs. [redacted] described very briefly the Agency's interest in behavioral agents, emphasizing the need to maintain constant surveillance of developments in this area and to provide a protective shield against potential hostile employment of these agents on U.S. officials. Also, the need for strict security concerning Agency interest in this area was especially emphasized. Mr. [redacted] assured us that the matter would be held very closely within the group present with the exception of the Director, who would be informed that the meeting had taken place.

4. It was agreed that future liaison would be handled through Dr. [redacted] and that such cooperation would include periodic briefings on new developments at BNDD.

5. It appears that the activities of BNDD, on-going and planned, could under the appropriate arrangements provide valuable information to the Agency in new drug effects, drug abuse and drug traffic areas. For this reason they will be followed very closely.